B‑Cell Lymphoblastic Leukemia Monitoring, Measurable/Minimal Residual Disease Detection, Flow Cytometry, Varies

Casandra

Casandra Test Code MC50816Version 1 (DRAFT)

Performing Lab

Lab Mayo Clinic LabLab Test ID BALLMCPT Codes 88184, 88185, 88188

B‑Cell Lymphoblastic Leukemia Monitoring, Measurable/Minimal Residual Disease Detection, Flow Cytometry, Varies

Clinical Use

Use

This test is appropriate only for patients with a previously confirmed diagnosis of B‑cell acute lymphoblastic leukemia (B‑ALL) and is used to monitor minimal residual disease (MRD) with high sensitivity (down to 0.002%), thus providing important prognostic information following therapy including induction or transplant. Immunophenotyping helps establish an immunophenotypic fingerprint of tumor cells to guide monitoring post-therapy or transplant. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/608251?utm_source=openai))

Special Instructions

A copy of the diagnostic flow cytometry report is required. If not ordering electronically, a Hematopathology/Cytogenetics Test Request (T726) form must be included. Shipping instructions: specimens must be received within 72 hours of collection. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/608251?utm_source=openai))

Limitations

Test is only appropriate for patients with a previously confirmed diagnosis of B‑ALL. Treatment with anti‑CD19 antibodies may interfere with MRD detection. Gross hemolysis in the specimen may result in rejection. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/608251?utm_source=openai))

Test Details

New York Approved